- The P-III MAIA study results involve assessing of Darzalex + lenalidomide + dexamethasone (Rd) vs Rd in 737 patients with newly diagnosed multiple myeloma ineligible for high-dose CT & ASCT aged 45-90 yrs.
- The P-III MAIA study results: reduction in risk of disease progression (44%); ORR (92.9% vs 81.3%); CR (47.6% vs 24.9%); MRD-negative (24.2% vs 7.3%)
- Darzalex is an Ab targeting CD38, inhibiting the tumor cell growth and has received FDA’s approval in Nov’15 as monothx. & in combination with Rd in Nov’16 for multiple myeloma prior treated with 3L & 1L therapy respectively
Click here to read full press release/ article | Ref: Janssen | Image: GMP news